Celularity, Inc. (NASDAQ:CELU – Get Free Report) was the target of a significant decline in short interest in September. As of September 15th, there was short interest totaling 821,020 shares, a decline of 56.7% from the August 31st total of 1,897,722 shares. Currently, 3.4% of the shares of the stock are short sold. Based on an average daily volume of 393,553 shares, the short-interest ratio is currently 2.1 days.
Celularity Stock Performance
Shares of CELU traded down $0.04 during trading hours on Tuesday, hitting $1.36. 21,153 shares of the stock were exchanged, compared to its average volume of 1,436,695. Celularity has a 12-month low of $0.56 and a 12-month high of $2.55. The company has a market cap of $39.52 million, a price-to-earnings ratio of -0.41 and a beta of 0.79. The stock’s 50-day moving average price is $1.08 and its two-hundred day moving average price is $1.01.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings raised shares of Celularity from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 27th. One analyst has rated the stock with a Sell rating, According to MarketBeat, Celularity has a consensus rating of “Sell”.
Institutional Investors Weigh In On Celularity
An institutional investor recently bought a new stake in Celularity stock. C V Starr & Co. Inc. purchased a new stake in shares of Celularity, Inc. (NASDAQ:CELU – Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 764,069 shares of the company’s stock, valued at approximately $1,582,000. Celularity comprises approximately 0.8% of C V Starr & Co. Inc.’s portfolio, making the stock its 4th biggest holding. C V Starr & Co. Inc. owned approximately 2.64% of Celularity as of its most recent filing with the SEC. 19.02% of the stock is currently owned by institutional investors and hedge funds.
Celularity Company Profile
Celularity, Inc is a biotechnology company developing allogeneic cell therapies and biomaterial products derived from human placenta. The company’s research focuses on using placental cells and tissues to address unmet needs in oncology, immune-mediated diseases and regenerative medicine.
Celularity’s therapeutic pipeline has included CYNK-001, an off-the-shelf natural killer cell therapy being investigated for certain blood cancers, as well as other engineered and unmodified placental-derived cell programs.
See Also
- Five stocks we like better than Celularity
- Tesla’s Semi Is Finally Here—But Will It Move the Stock?
- 5 Stocks Showing Why Pricing Power Matters More Than Government Money
- Rocket Lab Bounces Off Its Lows—What’s Behind the Move?
- NVIDIA Just Turned AI Safety Into a Spending Story and These 3 Stocks Benefit
Receive News & Ratings for Celularity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celularity and related companies with MarketBeat.com's FREE daily email newsletter.
